Could a custom vaccine stop cancer before it starts in lynch syndrome?
NCT ID NCT07163403
First seen Oct 31, 2025 · Last updated Jun 13, 2026 · Updated 28 times
Summary
This early-stage study tests a new vaccine made from a person's own immune cells to see if it can prevent cancer in people with Lynch syndrome, a genetic condition that raises cancer risk. The vaccine is designed to train the immune system to recognize and attack cells that might become cancerous. The study involves 20 adults with Lynch syndrome who have never had cancer, and will focus on safety and whether the vaccine triggers an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYNCH SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Laura Burunat
RECRUITINGBarcelona, Barcelona, 08036, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.